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We evaluated the RQ-mPCR (real-time quantitative PCR combined with multiplex PCR) 
assay, for quantification of Streptococcus pneumoniae and simultaneous detection of drug 
resistant genes by gel-based PCR, using purulent sputum samples. This assay correctly 
quantified S. pneumoniae and identified their penicillin- and erythromycin- susceptibilities, 
directly from samples within 3 h. 
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Streptococcus pneumoniae is a crucial pathogen that causes community-acquired pneumonia 
(CAP). CAP in adults is often treated with a combination of β-lactam antibiotics and 
macrolides (18, 22). However, alarmingly high frequencies of penicillin- and macrolide- 
resistant pneumococci have reported, especially in several Asian countries including Japan (4, 
24, 30). The resistance of S. pneumoniae to penicillin has been shown to be closely associated 
with mosaic mutations in the pbp1a, pbp2b, and pbp2x genes (12, 35). Macrolide resistance is 
generally mediated by two mechanisms: 23S rRNA methylation encoded by the erm(B) gene 
or macrolide efflux via the mef(A) gene (23, 32). Detection of drug-resistant S. pneumonaie by 
classical techniques usually takes several days (17, 27). Recently, the utility of real-time PCR 
method in the detection and quantification of S. pneumoniae have examined using lower 
respiratory tract samples (2, 5, 15, 20, 36). Their results suggest that clinical infection 
correlates with increased pneumococcal load, and they also mentioned the capacity of 
quantitative real-time PCR to distinguish between colonization and true infection (15, 36).  
Many investigators have evaluated the accuracy of multiplex PCR methods, which are used in 
the screening of S. pneumoniae strains possessing penicillin and macrolide resistance (13, 14, 
21, 33, 34). Most of these assays, however, require separate tubes, are only able to detect two 
or three gene fragments, and have not been evaluated for clinical respiratory tract samples.  
In the current studies, we developed a simultaneous single-tube real-time quantitative PCR 
combined with multiplex PCR (RQ-mPCR) assay that rapidly quantifies S. pneumoniae, 
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identifies alterations in pbp1a, pbp2b, and pbp2x genes, and detects the presence of erm(B) 
and mef(A) genes. We first verified this method using clinical S. pneumoniae strains and then 
evaluated the effectiveness of the method using purulent sputum samples.  
We used 200 clinical isolates of S. pneumoniae screened by optochin susceptibility 
(susceptible) and bile solubility (soluble) that were collected from April 2004 to March 2006 
by a laboratory at the Nagasaki University Hospital. Strains were propagated on 5% sheep 
blood agar (Nissui Co., Ltd., Tokyo, Japan) at 37°C with 5% CO2. A mixture of 24 bacterial 
species from ATCC (see Table S1 in the supplemental material) were selected from species 
commonly isolated from respiratory tract and from species that are genetically related to S. 
pneumoniae (3). In addition, 17 clinical strains of Streptococcus mitis and 12 clinical strains 
of Streptococcus oralis, which isolated from respiratory tract samples, were collected for 
cross-reactivity studies.  
The minimum inhibitory concentrations (MICs) were determined using broth microdilution 
techniques as described by the Clinical and Laboratory Standards Institute (CLSI) guidelines 
(7, 8). S. pneumoniae ATCC 49619 was used for quality control. 
A total of 200 purulent sputum samples, which were collected from April 2004 to March 
2005, and from June 2007 to August 2007 by a laboratory at the Nagasaki University Hospital, 
were used. Only good-quality sputum samples (P2 and P3 according to the classification of 
Miller and Jones (19)) were used. Sputum samples were diluted 1:100 and 1:10,000 with 
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0.45% sodium chloride and treated with SPUTAZYME solution (Kyokuto Pharmaceutical 
Industries Co., Ltd., Tokyo, Japan). The diluted samples were spread on 5% sheep blood agar 
plates with a DS500 spiral plater (InterScience Inc., Ontario, Canada) and then incubated in at 
37°C containing 5% CO2. Optochin sensitivity and bile solubility were used to identify S. 
pneumoniae.  Nucleic acids were isolated from clinical strains and sputum samples using the 
QIAamp DNA Blood Mini Kit (Qiagen, Hilden, Germany).  
The lytA, pbp1a, pbp2b, pbp2x, ermB, and mefA genes were amplified by PCR. Primers 
LytA-F and LytA-R and probes LytA-DCR and LytA-ACR were designed to target a 173-bp 
fragment of the single copy autolysin (lytA) gene of S. pneumoniae and were gleaned from 
published sequence (26). The primers for amplification of the pbp1a, pbp2b, and pbp2x genes 
were newly designed as follows: pbp1a (353 bp), 
5’-1709AGTATATCAAGAACACTGGCTACG1732 and 
5’-2061GCTTGGAGTGGTTGAGCTA2079-3’; pbp2b (442 bp), 
5’-1291AAATTGGCATATGGATCTTTTC1312-3’ and 
5’-1732TATTCATCTCTGTCGGTTGC1751-3’; pbp2x (339 bp), 
5’-990AAGTAACTATGAACCAGGATCAG1012-3’ and 
5’-1388CGAAGCATTTGTGTTTGTGT1407-3’. The resistance pbp1a primers were designed to 
target four amino acid substitutions (Thr-574→Asn, Ser-575→Thr, Gln-576→Gly, and 
Phe-577→Thr) that are common to all penicillin G-intermediate and -resistant isolates (29). 
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The resistance pbp2x primers were designed to target amino acid substitutions in the 
337STMK motif, and the resistance pbp2b primers were designed to target amino acid 
substitutions close to the 448SSN motif (25, 28). The primers for amplification of the ermB 
(224bp) and mefA (294bp) genes were gleaned from a published sequence (21). All of the 
primers used for RQ-mPCR had almost identical annealing temperatures (range from 59.0 °C 
to 62.5°C), which reduces the occurrence of unwanted bands originating from nonspecific 
amplification.  The PCR product amplified from S. pneumoniae ATCC49619 using the 
LytA-F and LytA-R primer set was ligated into the pTAC-1 plasmid vector (BioDynamics, 
Tokyo, Japan) using the TA PCR cloning technique.  Plasmid standards containing 2.9×106 
to 2.9×100 copies/μL were prepared by diluting the plasmid extracts in water.  The standard 
curve was generated and exported using LightCycler Software (v3.5).  PCR was performed 
on a LightCycler instrument. The final 20-μl single-tube reaction mixture contained 2× 
LightCycler FastStart DNA Master HybProbe (Roche Diagnostics, Basal, Switzerland), 5 mM 
MgCl2, 0.5 μM of each primer (LytA-F, LytA-R, pbp1a-F, pbp1a-R, pbp2b-F, pbp2b-R, 
pbp2x-F, pbp2x-R, mef-F, mef-R, erm-F, and erm-R), 0.2 μM of each hybridization probe 
(LytA-DCR and LytA-ACR), and 2 μl of DNA template. The cycling conditions were as 
follows: 95ºC for 10 min, followed by 40 cycles of 95ºC for 5 s, 60ºC for 10 s, and 72ºC for 
15 s. All runs included a negative control of water and a calibrator/positive control of 2.9×106 
copies/μl of the plasmid used for the standard curve. Data was analyzed using LightCycler 
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Software (v3.5) in the F2/F1 mode with a fit point calculation method. Following 
amplification, 10 μl of PCR product was separated by electrophoresis on a 3% agarose gel 
(Cambrex Bio Science Rockland, Inc. Rockland, ME, USA) for 30 min at 100 V. The 
positions of DNA fragments are shown in Figure 1A (Lane M, 100 Base-Pair Ladder 
(Amersham Biosciences)). Figure 1B shows the presence of the amplified products after 
agarose gel electrophoresis when DNA was extracted from representative PCG- and 
EM-resistant S. pneumoniae strains (lane 1, ATCC 49619 (MIC of PCG 0.25 μg/mL and EM 
<0.5 μg/mL); lane 2, clinical strain 4808/S (MIC of PCG <0.015 μg/mL and EM <0.5 
μg/mL); lane 3, clinical strain 1512/F (MIC of PCG 0.03 μg/mL and EM 2 μg/mL); lane 4, 
clinical strain 1565/F (MIC of PCG 0.03 μg/mL and EM 32 μg/mL); lane 5, clinical strain 
8315/F (MIC of PCG 0.12 μg/mL and EM 0.5 μg/mL); lane 6, clinical strain 4827/F (MIC of 
PCG 0.12 μg/mL and EM 32 μg/mL); lane 7, clinical strain 8605/Z (MIC of PCG 8 μg/mL 
and EM <0.5 μg/mL); lane 8, clinical strain 8729/Z (MIC of PCG 4 μg/mL and EM 8 
μg/mL); lane 9, clinical strain 1824/F (MIC of PCG 2 μg/mL and EM 16 μg/mL); lanes M, 
100 Base-Pair Ladder). 
Six S. pneumoniae ATCC strains were all positive for the lytA gene. None of the DNA 
extracts (≥10 ng/μl) from 47 non-pneumococcal organisms (including 17 clinical isolates of S. 
mitis and 12 clinical isolates of S. oralis) crossreact with the primer/probe set, showed the 
lytA primer/probe set was 100% specific for detecting S. pneumoniae strains.  We used S. 
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pneumoniae ATCC 49619 (positive for lytA and pbp1a), S. pneumoniae clinical strain 4808/S 
(positive for lytA only), and S. pneumoniae clinical strain 1824/F (positive for lytA, erm(B), 
mef(A), pbp1a, pbp2x, and pbp2b) to examine the analytical sensitivity of S. pneumoniae 
quantification by RQ-mPCR (see Figure S1-A in the supplemental material). The detection 
limit of lytA quantification was 20 copies/assay (10 copies/μl), which correspond to 5×102 
colony forming units (CFU)/mL. To verify the analytical sensitivities of drug resistance genes 
in RQ-mPCR, we used S. pneumoniae clinical strain 1824/F and assessed the appearance of 
PCR products by gel electrophoresis (see Figure S1-B in the supplemental material). The 
detection limits of the five drug resistant genes were between 5.8×101 and 5.8×102 
copies/assay (between 1×103 and 1×104 CFU/mL). To validate the RQ-mPCR technique, all 
of the 200 S. pneumoniae strains that were tested by RQ-mPCR were also screened for the 
presence of individual resistance genes by single PCR using the above PCR conditions. The 
results of the two methods were in full agreement (data not shown), suggesting that the 
multiplex PCR primer sets are reliable. The RQ-mPCR results of 200 S. pneumoniae strains 
and the MIC distribution of penicillin G and erythromycin are shown in Table 1. All of the 
200 strains were positive for the lytA gene. The multiplex PCR correctly identified penicillin 
susceptibility (MIC ≤0.06 μg/mL) or non-susceptibility (MIC ≥0.12 μg/mL) in 189 (94.5%) 
out of 200 isolates evaluated. The sensitivity, specificity, positive predictive values and 
negative predictive values of our assay were 98.1% (103/105), 90.5% (86/95), 91.9% 
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(103/112), and 97.7% (86/88), respectively.  Our assay also correctly identified erythromycin 
susceptibility (MIC ≤0.5 μg/mL) or resistant (MIC ≥1 μg/mL) in 200 (100%) out of 200 
isolates evaluated. All of these isolates yielded 100% sensitivity, 100% specificity, 100% 
positive predictive values and 100% negative predictive values.  
Of 200 purulent sputum samples, 56 samples were S. pneumoniae-positive, and the 
remaining 144 samples were S. pneumoniae-negative as determined by the conventional 
culture method. All 56 S. pneumoniae-positive samples were also positive for the lytA gene, 
and 143 of the 144 S. pneumoniae-negative samples were negative for the lytA gene. 
Therefore, the sensitivity and specificity for identification of S. pneumoniae using purulent 
sputum samples in RQ-mPCR compared to the conventional culture method was 100% 
(56/56) and 99.3% (143/144). The correlation between the conventional culture counts and 
the level of lytA gene expression by RQ-mPCR using the 56 pneumococcal culture-positive 
sputum samples is shown in Figure S2 in the supplemental material.  
The penicillin- and macrolide-resistant genes detected by RQ-mPCR in purulent sputum 
samples are shown in Table 2. We compared these results to those in isolated S. pneumoniae 
from the same sputum samples. Of 56 pneumococcal culture-positive sputum samples, all 
were positive for lytA gene, and for 51 samples, the detected genes were in complete 
agreement with isolated S. pneumoniae. For the remaining five samples, the genes were not in 
complete agreement with isolated S. pneumoniae: two samples were false positives for 
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erm(B); one sample was false positive for mef(A), pbp1a, pbp2x, and pbp2b; one sample was 
false positive for pbp2x and pbp2b; and one sample was false positive for mef(A) and a false 
negative for pbp1a. The sensitivity and specificity of this assay for detecting genes directly 
from sputum samples relative to isolated S. pneumoniae were 100% and 93.9% for erm(B), 
100% and 94.8% for mef(A), 94.4% and 97.5% for pbp1a, 100% and 94.1% for pbp2x, and 
100% and 95.6% for pbp2b. With regard to the 144 pneumococcal culture-negative sputum 
samples, the detection rates of drug resistant genes were 0% for pbp1a, 2.7% (4/144) for 
pbp2x, 1.4% (2/144) for pbp2b, 20.8% (30/144) for erm(B), and 11.1% (16/144) for mef(A). 
Microorganisms closely related to S. mitis and harboring lytA gene, which are classically 
associated with S. pneumoniae, have been reported previously (37). However, positive results 
were not obtained from the mitis group of Streptococci (including our collected clinical 
strains of 17 S. mitis and 12 S. oralis) that were tested for cross-reactivity in this study. 
Compared to past reports (13, 14, 21, 34, 35), we obtained lower pbp2b detection rates in 
PCG-intermediate S. pneumoniae strains. This may have been due to a difference in the 
regions targeted by the pbp2b primers. The PCR results of macrolide resistant genes in this 
study matched previous report using the same primers (21), and they were also consistent 
with reports using other primers (11, 31). Although the analytical sensitivities of resistance 
genes on gel electrophoresis was lower than that of lytA quantification, the detection limit of 
1×103 to 1×104 CFU/mL in resistant strains is within the permissible range for use with 
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clinical samples, including bronchoalveolar fluid, which requires a diagnostic sensitivity for 
pathogens in excess of 104 CFU/mL (1, 9).  With regard to one sputum sample which 
showed a false positive for the lytA gene, the RQ-mPCR assay (confirmed repeatedly) showed 
the presence of 1×104 CFU/mL of S. pneumoniae, and this specimen grew to 2×107 CFU/mL 
of Staphylococcus aureus by culture method.  This discrepancy may have resulted from a 
failure to detect S. pneumoniae that was surrounded by S. aureus, and/or have resulted from 
the detection of atypical S. mitis or S. oralis, both of which harbor the lytA gene (37).   
A discrepancy in RQ-mPCR specificity for samples 102/5F01 (false positive for mef(A)), 
107/5F23 (false positive for pbp2x and pbp2b), 113/5F28 (false positive for mef(A), pbp1a, 
pbp2x, and pbp2b), and 101/6S11 and 101/6D13 (false positive for erm(B)) was confirmed by 
single PCR. This discrepancy indicates the presence of similar resistance genes in other 
microorganisms in the sputum samples. Avoiding these problems with crossreactivity is 
currently difficult because the mosaic genes that encode altered, low-affinity pbp genes are 
considered products of recombination events involving horizontal transfer from closely 
related species (10, 16) and also because erm(B) and mef(A) macrolide resistant genes in S. 
pneumoniae are highly homologous to genes in other Streptococcus-related species (6). In 
sample 102/5F01, pbp1a was detected by a single PCR, suggesting that the discrepancy in 
sensitivity (false negative) was due to the presence of PCR inhibitors or a decline of 
sensitivity in this sputum sample. Although the sensitivity and specificity rates of our assay 
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for sputum samples were in general satisfactory, further investigations are needed to remove 
PCR inhibitors from samples and to increase the sensitivity of the assay. Although our 
RQ-mPCR assay showed high correlation between the conventional culture counts and the 
level of lytA gene expression, further data from patients with pneumonia is needed to evaluate 
and interpret the results of our assay. 
In summary, the RQ-mPCR method developed here had high sensitivity and 
specificity for pneumococci and could detect drug resistance in both clinical S. pneumoniae 
strains and in sputum samples. Furthermore, the results can be obtained directly from clinical 
samples within 3 h (2h for DNA extraction and preparation of PCR mixture, and 1h for PCR 
assay and electrophoresis), and this assay requires only a single tube. This method may be 
helpful for the rapid screening of resistance in pneumococcal isolates, and should allow the 
administration of earlier, more focused and effective treatment of drug-resistant S. 
pneumoniae.  
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Figure 1. New multiplex PCR assay for simultaneous detection of lytA, penicillin 
resistance genes (altered pbp1a, pbp2x, and pbp2b), and macrolide resistance genes 
(erm(B) and mef(A)). 
(A) Comparison of single target versus multiplex PCR using “resistant” control strain 1824/F. 
Lane M, 100 Base-Pair Ladder (Amersham Biosciences). (B) Agarose gel electrophoresis of 
PCR products amplified with RQ-mPCR using control strains. Lane 1, ATCC 49619 (MIC of 
0.25 μg/mL for PCG and <0.5 μg/mL for EM); lane 2, clinical strain 4808/S (MIC of <0.015 
μg/mL for PCG and <0.5 μg/mL for EM); lane 3, clinical strain 1512/F (MIC of 0.03 μg/mL 
for PCG and 2 μg/mL for EM); lane 4, clinical strain 1565/F (MIC of 0.03 μg/mL for PCG 
and 32 μg/mL for EM); lane 5, clinical strain 8315/F (MIC of 0.12 μg/mL for PCG and 0.5 
μg/mL for EM); lane 6, clinical strain 4827/F (MIC of 0.12 μg/mL for PCG and 32 μg/mL for 
EM); lane 7, clinical strain 8605/Z (MIC of 8 μg/mL for PCG and <0.5 μg/mL for EM); lane 
8, clinical strain 8729/Z (MIC of 4 μg/mL for PCG and 8 μg/mL for EM); lane 9, clinical 
strain 1824/F (MIC of 2 μg/mL for PCG and 16 μg/mL for EM); lanes M, 100 Base-Pair 
Ladder (Amersham Biosciences). 
 
 
Legends of Supplemental Figures 
 
Figure S1. Analytical sensitivity of S. pneumoniae quantification and identification of 
resistant genes by RQ-mPCR assay using S. pneumoniae strains.  
(A) Comparison of plasmid and genomic DNA standard curves of S. pneumoniae strains in 
lytA amplification using RQ-mPCR. The horizontal axis represents concentrations 
(copies/assay) of plasmid and genomic DNA of S. pneumoniae strains, and the vertical axis 
represents the crossing point (Cp) obtained by the RQ-mPCR method. Dark circles represent 
plasmid, white circles represent ATCC 49619, white triangles represent strain 4808/S, and 
white squares represent strain 1824/F. DNA purified from 0.5 McFarland S. pneumoniae 
strains was quantified by comparison with the plasmid standard curve and adjusted to 2.9×106 
target copies/μL. Ten-fold of serial dilutions of plasmid and genomic S. pneumoniae DNA 
were amplified in duplicate, and standard curves were plotted for each. Amplification of 
plasmid DNA was linear from 106 to 101 copies/assay. Comparison of the curves gave a 
correlation coefficient of 0.9946, indicating that the plasmid standard curve was accurate for 
the genomic S. pneumoniae DNA. The detection limit of lytA quantification was 20 
copies/assay (10 copies/μl). (B) Identification of sensitivities for detection of resistance genes 
by the RQ-mPCR method using serial 10-fold dilutions of S. pneumoniae strain 1824/F. 
Ten-fold of serial dilutions of DNA purified from 0.5 McFarland (2.9×106 target copies/μL) S. 
pneumoniae strain 1824/F were amplified by RQ-mPCR. Lane M, 100 Base-Pair Ladder 
(Amersham Biosciences). Bands were observed for lytA (173 bp), erm(B) (224 bp), mef(A) 
(294 bp), pbp1a (353 bp), pbp2x (399 bp), and pbp2b (442 bp). Multiplex PCR containing the 
lytA primer/probe set and primers for erm(B), mef(A), pbp1a, pbp2x, and pbp2b followed by 
gel electrophoresis could reliably detect 5.8×102 copies/assay (29 copies/μl). Six weak bands 
were detected using 5.8×101 copies/assay, but no bands were observed using 5.8×100 
copies/assay.  
 
Figure S2. Correlation between lytA quantification by RQ-mPCR and numbers of CFU 
by conventional culture for 56 pneumococcal culture-positive sputum samples. 
Solid circles represent sputum samples (n=56). The logarithm of CFU counts determined by 
conventional culture is plotted on the horizontal axis, and the logarithm of the DNA copy 
number of lytA as determined by RQ-mPCR is plotted on the vertical axis. The correlation 
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Gram positive and negative bacteria and C. albicans were  tested as a neat extract of a 0.5 Mcfarland. 
Candida albicans ATCC 14053 negative




clinical strains (n=17) negative
negativeclinical strains (n=12)
Table 2.   RQ-mPCR results and MICs of penicillin G and erythromycin in 200 pneumococcal isolates
MIC (μg/ml) distribution of PCG
≤0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 8
RQ-mPCR 
results


















16 20 18 1
MIC (μg/ml) distribution of EM

















Abbreviations: PCG, penicillin-G; EM, erythromycin. The CLSI MIC breakpoints for S. pneumoniae are as follows: PCG, susceptible 
≤0.06μg/ml, intermediate 0.12-1μg/ml, resistant ≥2μg/ml; EM, susceptible ≤0.25μg/ml, intermediate 0.5μg/ml, resistant ≥1μg/ml 7). 
no. of pneumococcal 
culture positive samples
lytA erm(B) mef(A) pbp1a pbp2x pbp2b
no. of gene positive sputum samples by RQ-mPCR
samples with 
complete agreement
b 51 27 19 15 24 12
(n=56) 
Table 3.  
a 51 / 56
samples with 
disagreement




99.3 % 93.9 %





94.1 % 95.6 %
100 %
c (no. of false positive / no. of false negative).  
Comparison of RQ-mPCR results between in pneumococcal positive sputum samples 
and in isolated S. pneumoniae.
(n=5) 
a no. of samples with complete agreement to RQ-mPCR results in isolated S. pneumoniae / no. of all samples.  


































Abbreviations: FP, false-positive; FN, false-negative.  






































































Gram positive and negative bacteria and C. albicans were  tested as a neat extract of a 0.5 Mcfarland. 
Candida albicans ATCC 14053 negative




clinical strains (n=17) negative
negativeclinical strains (n=12)
